Cytosorbents Corp
CTSO Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$4.47
KIRA · Stoqly’s AI analyst, in plain words
- Cytosorbents Corp had $37.1M of revenue in fiscal 2025, up 4.1% on the year before. Over five years, revenue changed −2.0% a year on average.
- Its operating margin was −39.8%, up 6.4 pts: of every 100 in sales, about −40 is left after running the business.
- Cytosorbents Corp lost $8.2M in fiscal 2025.
- Free cash flow was −$12.5M in fiscal 2025, −33.8% of revenue.
- Cytosorbents Corp owes $10.4M more than it holds in cash.
Market cap
$281M
P/E
—
Revenue
$37.1M
Net income
−$8.2M
Free cash flow
−$12.5M
Operating margin
−39.8%
Cytosorbents Corp in 30 seconds · fiscal 2025
Are sales growing?
+4.1%
Only a little. Sales grew 4.1% last year.
Does it make a profit?
−22.1%
No. It lost money last year.
Does profit turn into cash?
−33.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cytosorbents Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Cytosorbents Corp
- CIK
- 0001175151
Cytosorbents Corp · CTSO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $43.2M | $34.7M | $31.1M | $35.6M | $37.1M |
| Revenue growth | 5.3% | −19.6% | −10.4% | 14.5% | 4.1% |
| Gross margin | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating margin | −52.7% | −90.9% | −102.8% | −46.2% | −39.8% |
| Net income | −$24.6M | −$32.8M | −$29.2M | −$20.7M | −$8.2M |
| Net margin | −56.9% | −94.6% | −94.1% | −58.2% | −22.1% |
| Diluted EPS | −$0.57 | −$0.75 | −$0.65 | −$0.38 | −$0.13 |
| Cash | |||||
| Cash from operations | −$14.0M | −$28.2M | −$21.7M | −$14.4M | −$12.4M |
| Capital expenditure | $3.6M | $6.1M | $0.5M | $0.3M | $0.2M |
| Free cash flow | −$17.6M | −$34.3M | −$22.2M | −$14.7M | −$12.5M |
| FCF margin | −40.9% | −98.9% | −71.4% | −41.3% | −33.8% |
| Share count change | 11.7% | 0.5% | 2.5% | 21.9% | 14.3% |
| Debt and strength | |||||
| Cash and short-term investments | $52.1M | $22.1M | $14.1M | $3.3M | $6.2M |
| Debt incl. finance leases | — | $5.0M | $5.0M | $14.0M | $16.7M |
| Shareholders' equity | $62.6M | $35.4M | $23.5M | $11.1M | $5.9M |
| Current ratio | 4.7x | 3.5x | 1.8x | 2.2x | 2.1x |
| Returns and quality | |||||
| Return on capital | — | −136.6% | −175.4% | −59.6% | −71.4% |
| Return on equity | −34.6% | −67.0% | −99.4% | −119.8% | −96.4% |
| Return on tangible equity | −42.4% | −105.9% | −149.4% | −280.5% | −306.2% |
| Piotroski F-score | 3 | 2 | 3 | 4 | 3 |
| Altman Z'' | −3.6 | −12.6 | −19.2 | −21.3 | −23.5 |
Insiders bought, 12 months
$0.3M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cytosorbents Corp · CTSO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.47 a share, the company is worth $281M.
Source: SEC EDGAR XBRL filings (CIK 0001175151). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.